PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November: Guggenheim Global Healthcare Conference: Fireside chat on Monday, November 11, 2024, at 3:00 p.m. ET in Boston, MA. UBS Global Healthcare Conference: Fireside chat on Wednesday, November 13, 2024, at 11:45 a.m. PT in Rancho Palos Verdes, CA. Stifel 2024 Healthcare Conference: Presentation on Tuesday, November 19, 2024 at 1:50 p.m. ET in New York, NY. Context will also participate in one-on-one meetings a

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title:Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6Authors:Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, Eric ButzAbstract Number:

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. ("BioAtla") (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ("CAB") antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. ("Context") (NASDAQ:CNTX), a biopharmaceutical company advancing

PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. "Karen and Luke's vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. "Karen's extensive oncology drug development, regulatory, and strategy experience will be invaluable as Context continues to advance its pipeline. Luke brings an extensive track record in

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlights. "Context continues to build momentum, and we believe the Company is well positioned to have a successful year," said Martin Lehr, CEO of Context. "Our team recently initiated our Phase 1 trial

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell engaging assets to treat solid tumors PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer ("CMO") and Karen Andreas, M.S. as Vice President, Clinical Operations. "We are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas to our team at this exciting time as the Company adv

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. ("Link"), a mesothelin ("MSLN") x CD3 T cell engaging ("TCE") bispecific antibody with first-in-class potential that has received Investigational New Drug ("IND") clearance from th

Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights. "We believe Context has had a great start to 2024 including achieving significant regulatory goals, demonstrating robust progress, and positioning us for future growth. The Company successfully closed a private placement, generating

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for CTIM-76, a Claudin 6 ("CLDN6") x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular ca

Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds of approximately $100.0 million, before deducting placement agent fees and estimated offering expenses. The private placement is expected to close on May 6, 2024, su

Piper Sandler initiated coverage of Centrexion Therapeutics with a rating of Overweight and set a new price target of $4.50

HC Wainwright & Co. initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $6.00

ThinkEquity initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $10.00

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlights. "Context continues to build momentum, and we believe the Company is well positioned to have a successful year," said Martin Lehr, CEO of Context. "Our team recently initiated our Phase 1 trial

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. ("Link"), a mesothelin ("MSLN") x CD3 T cell engaging ("TCE") bispecific antibody with first-in-class potential that has received Investigational New Drug ("IND") clearance from th

Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights. "We believe Context has had a great start to 2024 including achieving significant regulatory goals, demonstrating robust progress, and positioning us for future growth. The Company successfully closed a private placement, generating

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights. "During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6") x CD3 bispecific antibody, toward a first-

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights. "During the third quarter of this year, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6") x CD3 bispecific antibody, towa

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights. "During the second quarter of this year, Context continued development of our preclinical asset CTIM-76, a Claudin 6 ("CLDN6") x CD3 bispecific antibody. An i

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced its financial results for the first quarter ended March 31, 2023, and reported on recent and upcoming business highlights. "During the first quarter of this year, Context announced a portfolio prioritization to focus solely on the development of our preclinical a

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR+ recurrent endometrial cancer ONA-XR continues to exhibit favorable safety and tolerability profile Cash and cash equivalents of $39 million as of September 30, 2022, expected to provide runway into Q1 2024 PHILADELPHIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a women's oncology company developing novel treatments for breast and gynecologic cancers, today reported on recent and upcoming business

HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.

CT-95, formerly owned by Link Immunotherapeutics, a mesothelin x CD3 T cell engaging bispecific antibody with first-in-class potential that has received Investigational New Drug clearance from the U.S. Food and Drug Administration. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. CT-95 is an IND-cleared asset that it plans to rapidly progress into clinical trials. It intends to fund the acquisition of CT-95 and its advancement through the dose escalation portion of a Phase 1 clinical trial with existing cash.

- SEC Filing

Piper Sandler analyst Joseph Catanzaro initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating and announces Price Target of $4.5.

- SEC Filing

-SEC Filing

HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.

Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $10.

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.38) by 39.47 percent. This is a 42.5 percent increase over losses of $(0.40) per share from the same period last year.

Gainers FibroGen (NASDAQ:FGEN) shares rose 37.1% to $1.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $158.1 million. The company's, Q1 earnings came out yesterday. Envoy Medical (NASDAQ:COCH) stock moved upwards by 23.54% to $4.25. The company's market cap stands at $83.2 million. iSpecimen (NASDAQ:ISPC) shares rose 21.18% to $0.33. The company's market cap stands at $3.0 million. The company's, Q1 earnings came out today. NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 20.87% to $0.11. The company's market cap stands at $3.9 million. GT Biopharma (NASDAQ:GTBP) shares rose 19.25% to $3.84. The market value of their outstanding shar

SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)